严重精神障碍患者接种新冠病毒疫苗的不良反应调查研究
Adverse reactions of COVID-19 vaccine in patients with severe mental disorders
ES评分 0
| DOI |
| 刊名 |
Journal of International Psychiatry
|
| 年,卷(期) |
2023, 50(1) |
| 作者 |
|
| 作者单位 |
重庆市江北区精神卫生中心 ;
|
| 摘要 |
【摘要】探索严重精神障碍患者接种新冠病毒疫苗的不良反应。方法 于2021年5月1日至2021年5月25日在重庆市江北区、万州区以街镇为单位整群选取在国家严重精神障碍管理治疗系统居家在管患者中接种新冠病毒疫苗患者412例为调查对象,采用国家药品监督管理局发布的不良事件反应分级表、 PANSS阳性症状量表评估患者接种新冠病毒后一周内的不良反应及阳性症状发生情况。结果 接种新冠病毒严重精神障碍患者疫苗严重不良事件发生率为0,一般不良反应发生率为9.5%,接种疫苗患者一周内阳性症状发生率为3.2%,不良事件发生与阳性症状发生之间存在相关关系(=0.131,P=0.008),Logistic回归分析结果显示,发生不良事件(OR=4.68)是阳性症状出现的高风险因素。结论 严重精神障碍患者接种新冠病毒疫苗的不良反应发生率低,安全性高,不良事件是阳性症状出现的高风险因素。
|
| Abstract |
【Abstract】Objective To explore the adverse reactions of COVID-19 vaccine in patients with severe mental disorders. Methods A total of 412 severe mental disorders cases who get vaccinated against COVID-19 were selected from the home management patients in the national severe mental disorder management system from May 1, 2021 to May 25, 2021, in Chongqing Jiangbei District and Wanzhou District. Adverse event response rating scale issued by the China State Food and Drug Administration and PANSS positive symptom scale was used to evaluate the adverse reactions and positive symptoms within one week after inoculation of COVID-19. Results The incidence of serious adverse events in patients with severe mental disorders was 0, the incidence of general adverse reactions was 9.5%, the incidence of positive symptoms within one week was 3.2%, and there was a correlation between adverse reactions and positive symptoms (=0.131, P=0.008). Logistic regression analysis showed that adverse reactions (OR=4.68) is a high risk factor for the occurrence of positive symptoms. Conclusions The incidence of adverse reactions to COVID-19 vaccine in patients with severe mental disorders is low, and the safety is high. Adverse events is a high risk factor for positive symptoms.
|
| 关键词 |
严重精神障碍;新冠病毒;疫苗
|
| KeyWord |
severe mental disorders; COVID-19; vaccine
|
| 基金项目 |
|
| 页码 |
86-88 |
史战明*.
严重精神障碍患者接种新冠病毒疫苗的不良反应调查研究 [J].
国际精神病学杂志.
2023; 50; (1).
86 - 88.